Positive Buy Rating for NovoCure Driven by Promising PANOVA-3 Trial Results in Pancreatic Cancer Treatment

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on NovoCure (NVCR – Research Report), retaining the price target of $38.00.

Emily Bodnar’s rating is based on the promising results from NovoCure’s PANOVA-3 trial, which demonstrated a significant overall survival benefit for patients with locally advanced pancreatic cancer when treated with TTFields therapy in combination with standard chemotherapy. The trial showed a median overall survival of 16.2 months in the treatment arm, compared to 14.16 months in the control group, marking a statistically significant improvement.
Additionally, the therapy provided notable improvements in quality of life and pain-free survival, despite some manageable side effects like localized skin reactions. The company plans to submit the data for regulatory approval, and there is confidence in the potential FDA approval due to the unmet needs in pancreatic cancer treatment. The anticipated launch in 2026 and ongoing trials further support the positive outlook for TTFields therapy, contributing to the Buy rating.

In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $40.00 price target.